DNA vaccine expressing HIV-1 gp120/immunoglobulin fusion protein enhances cellular immunity

Shimada, Masaru; Yoshizaki, Shinji; Jounai, Nao; Kondo, Asami; Ichino, Motohide; Ryo, Akihide; Okuda, Kenji

doi:10.1016/j.vaccine.2010.05.035

Cited by 9 publications

(11 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other fusion sequences have been reported to enhance the immune response. In the case of the HIV gp120, fusion to an IgG provided a more effective protection against a chimera virus challenge (Shimada et al, 2010), and MIPa chemokine helped for APC targeting (Ruffini et al, 2010). Fusion of the host-derived component of complement C3d to the extracellular region of murine VEGFR-2 led to a significantly increased survival in mice melanoma and colon cancer models by inducing a strong humoral response , with similar findings in a bladder cancer model (Liang et al, 2010).…”

Section: Adjuvantsmentioning

confidence: 62%

Genetic Immunization with Plasmid DNA Mediated by Electrotransfer

2011

View full text Add to dashboard Cite

The concept of DNA immunization was first advanced in the early 1990s, but was not developed because of an initial lack of efficiency. Recent technical advances in plasmid design and gene delivery techniques have allowed renewed interest in the idea. Particularly, a better understanding of genetic immunization has led to construction of optimized plasmids and the use of efficient molecular adjuvants. The field also took great advantage of new delivery techniques such as electrotransfer. This is a simple physical technique consisting of injecting plasmid DNA into a target tissue and applying an electric field, allowing up to a thousandfold more expression of the transgene than naked DNA. DNA immunization mediated by electrotransfer is now effective in a variety of preclinical models against infectious or acquired diseases such as cancer or autoimmune diseases, and is making its way through the clinics in several ongoing phase I human clinical trials. This review will briefly describe genetic immunization mediated by electrotransfer and the main fields of application.

show abstract

Section: Adjuvantsmentioning

confidence: 62%

Genetic Immunization with Plasmid DNA Mediated by Electrotransfer

2011

View full text Add to dashboard Cite

show abstract

“…Furthermore, pGp120Ig significantly reduced the viral load after challenge with an HIV Env gp160-expressing vaccinia virus. These results represented that covalent antigen modification with an Ig sequence can modulate antigen-specific cellular immune responses [37].…”

Section: Adjuvantsmentioning

confidence: 87%

“…These reports showed that cytokine-coding plasmids fused with Ig have higher expression efficiency and better adjuvanticity. Furthermore, these plasmids have features that make them useful such as augmentation of half life in vivo, formation of a multivalent antigen, and solubilization of hydrophobic proteins [37]. The possibility of increasing HIV gp120-specific cellular immune responses was determined in mice using a DNA vaccine encoding a mouse Ig fragment fused with gp120 in two directions (gp120-Ig or Ig-gp120).…”

Section: Adjuvantsmentioning

confidence: 99%

How can Improve DNA Vaccine Modalities as a Therapeutic Approach against HIV Infections?

Habibzadeh¹

2015

J AIDS Clin Res

View full text Add to dashboard Cite

“…The number of CD8 + T cells expressing T cell receptor (TCR) that recognized H-2D d /p18 tetramer was examined by tetramer assay. Tetramer assays were performed using a H-2D d /p18 tetramer as previously described (Shimada et al, 2010). Briefly, PBMCs were isolated from immunized mice, and stained with a PE-conjugated H-2D d /p18 tetramer and FITC-conjugated anti-mouse CD8a antibody.…”

Section: Methodsmentioning

confidence: 99%

“…Intracellular cytokine staining (ICS) assays were performed as previously described (Shimada et al, 2010). Briefly, PBMCs were obtained from immunized mice, and the red blood cells were removed using lysing buffer (BD Bioscience).…”

Section: Methodsmentioning

confidence: 99%

Vaccination with human induced pluripotent stem cells creates an antigen-specific immune response against HIV-1 gp160

et al. 2011

Self Cite

View full text Add to dashboard Cite

Induced pluripotent stem cells (iPSCs) are artificially derived from somatic cells that have been transduced with defined reprogramming factors. A previous report has indicated the possibility of using iPSCs as an immune stimulator to generate antigen-specific immunity. In our current study, we have investigated whether human iPSCs (hiPSCs) have the ability to enhance specific immune response against a human immunodeficiency virus type 1 (HIV-1) antigen in a xenogenic mouse model. Our results show that BALB/c mice immunized with hiPSCs transduced with an adenoviral vector encoding HIV-1 gp160 exhibited prominent antigen-specific cellular immune responses. We further found that pre-treatment of hiPSCs with ionizing radiation promotes the secretion of pro-inflammatory cytokines such as interleukin-1 alpha (IL-1α), IL-12, and IL-18. These cytokines might promote the activation of antigen-presenting cells and the effective induction of cellular immunity. Our present findings thus demonstrate that a hiPSCs-based vaccine has the potential to generate cellular immunity against viral antigens such as HIV-1 gp160 in a xenogenic condition.

show abstract

DNA vaccine expressing HIV-1 gp120/immunoglobulin fusion protein enhances cellular immunity

Cited by 9 publications

References 40 publications

Genetic Immunization with Plasmid DNA Mediated by Electrotransfer

Genetic Immunization with Plasmid DNA Mediated by Electrotransfer

How can Improve DNA Vaccine Modalities as a Therapeutic Approach against HIV Infections?

Vaccination with human induced pluripotent stem cells creates an antigen-specific immune response against HIV-1 gp160

Contact Info

Product

Resources

About